VistaGen Advances Refisolone Nasal Spray in U.S. Phase 2

VistaGen Therapeutics ( (VTGN) ) has shared an announcement.

On April 22, 2026, Vistagen announced it received an FDA “Study May Proceed” letter under its U.S. IND for refisolone nasal spray, a non-hormonal, non-systemic Phase 2 candidate for treating moderate to severe menopausal vasomotor symptoms. The clearance lets the company expand Phase 2 development in the U.S., building on prior exploratory Phase 2a studies in Mexico that also evaluated premenstrual dysphoric disorder.

In those Mexican Phase 2a data in menopausal women with frequent hot flashes, refisolone cut hot flash frequency by 80% versus 36% for placebo, with improvements seen as early as one week and no serious drug-related adverse events reported. The move deepens Vistagen’s push into women’s health and, if later-stage trials succeed, could strengthen its competitive position with a fast-acting, on-demand, non-hormonal alternative in a large, underserved market for menopausal symptom relief.

The most recent analyst rating on (VTGN) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on VistaGen Therapeutics stock, see the VTGN Stock Forecast page.

Spark’s Take on VTGN Stock

According to Spark, TipRanks’ AI Analyst, VTGN is a Neutral.

The score is held down primarily by weak financial performance (large ongoing losses and cash burn with minimal revenue) and bearish longer-term technicals (well below 100D/200D with negative MACD). The earnings call adds some support from program progress and cash-preservation actions, but significant trial/regulatory uncertainty persists, and corporate events introduce additional Nasdaq listing and governance overhang.

To see Spark’s full report on VTGN stock, click here.

More about VistaGen Therapeutics

Vistagen Therapeutics, based in South San Francisco, is a late clinical-stage biopharmaceutical company focused on neuroscience, developing a new class of rapid-onset, intranasal product candidates called pherines. Its clinical pipeline comprises five investigational therapies targeting prevalent conditions such as social anxiety disorder, major depressive disorder, and menopausal vasomotor symptoms, with products designed to act via nose-to-brain neurocircuitry without systemic absorption.

The company aims to position these pherine-based nasal sprays as potentially safer alternatives to traditional pharmacological treatments, emphasizing non-hormonal, non-systemic mechanisms that may avoid certain adverse events. By concentrating on large, underserved markets in mental health and women’s health, Vistagen is seeking to differentiate itself within the biotech sector and enhance its long-term growth prospects.

Average Trading Volume: 837,102

Technical Sentiment Signal: Sell

Current Market Cap: $23.53M

For detailed information about VTGN stock, go to TipRanks’ Stock Analysis page.